Market Research Logo

Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, “Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides an overview of Immunohaematology Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohaematology Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Immunohaematology Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunohaematology Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunohaematology Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Immunohaematology Diagnostic Tests Overview 6
3 Products under Development 7
3.1 Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development 7
3.2 Immunohaematology Diagnostic Tests - Pipeline Products by Segment 8
3.3 Immunohaematology Diagnostic Tests - Pipeline Products by Territory 9
3.4 Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path 10
3.5 Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date 11
4 Immunohaematology Diagnostic Tests - Pipeline Products under Development by Companies 12
4.1 Immunohaematology Diagnostic Tests Companies - Pipeline Products by Stage of Development 12
4.2 Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development 13
5 Immunohaematology Diagnostic Tests Companies and Product Overview 15
5.1 AbSorber AB Company Overview 15
5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 Amity University Company Overview 16
5.2.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Arizona State University Company Overview 17
5.3.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Haemonetics Corp Company Overview 18
5.4.1 Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 18
5.5 Immucor, Inc. Company Overview 19
5.5.1 Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.6 Ortho-Clinical Diagnostics Inc Company Overview 20
5.6.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 20
5.7 Quotient Limited Company Overview 22
5.7.1 Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 22
5.8 TBG Diagnostics Ltd Company Overview 28
5.8.1 TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
5.9 TheraDiag SA Company Overview 31
5.9.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 31
5.10 Transfusion & Transplantation Technologies (Inactive) Company Overview 39
5.10.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 39
6 Immunohaematology Diagnostic Tests - Recent Developments 45
6.1 Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 45
6.2 Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 51
6.3 Jun 22, 2017: Haemonetics Announces Formation of Scientific Advisory Council 52
6.4 May 22, 2017: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results 52
6.5 May 08, 2017: Haemonetics Reports 4th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance 54
6.6 May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results 56
6.7 May 03, 2017: Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million 57
6.8 Apr 27, 2017: THERADIAG Announces First-quarter 2017 Revenues 62
6.9 Apr 27, 2017: Theradiag: First-Quarter 2017 Revenues 62
6.10 Apr 03, 2017: U.S. District Judge Grants AllCells Motion for Preliminary Injunction in Lawsuit Against Cepheus Biosciences 62
6.11 Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors 63
6.12 Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day 64
6.13 Mar 01, 2017: Appointment of Dominique Costantini and Dominique Takizawa to Theradiag’s Board of Directors 65
6.14 Mar 01, 2017: THERADIAG: Full-year 2016 results 66
6.15 Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 68
6.16 Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 78
6.17 Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 80
6.18 Feb 09, 2017: Quotient Announces Appointment of Christopher Lindop as Chief Financial Officer 82
6.19 Feb 06, 2017: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Third Quarter Fiscal 2017 Financial Results 82
6.20 Jan 05, 2017: Quotient Reports Positive MosaiQ Results From Performance Evaluation Study for Blood Grouping 84
6.21 Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million 85
6.22 Nov 02, 2016: Quotient Announces CFO Transition 90
6.23 Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 90
6.24 Oct 31, 2016: Quotient Second Quarter Fiscal 2017 Financial Results 91
6.25 Oct 31, 2016: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Second Quarter Fiscal 2017 Financial Results 93
6.26 Oct 27, 2016: Catherine M. Burzik Joins Haemonetics Board of Directors 95
6.27 Oct 24, 2016: Immucor Announces CE Mark in Europe for NEO Iris; Next Generation, Fully Automated Instrument for Transfusion Medicine 96
6.28 Oct 20, 2016: AllCells Announces New Vice President, Manufacturing Operations 97
6.29 Oct 13, 2016: THERADIAG: Very strong revenue growth at end-September 2016: +31% 97
6.30 Sep 14, 2016: THERADIAG: First-half 2016 Revenues and Results 98
6.31 Aug 08, 2016: Quotient Reports Further Progress on the Commercial Scale-up of MosaiQ and First Quarter Fiscal 2017 Financial Results 99
7 Appendix 102
7.1 Methodology 102
7.2 About GlobalData 105
7.3 Contact Us 105
7.4 Disclaimer 105
1.1 List of Tables
Table 1: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development 7
Table 2: Immunohaematology Diagnostic Tests - Pipeline Products by Segment 8
Table 3: Immunohaematology Diagnostic Tests - Pipeline Products by Territory 9
Table 4: Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path 10
Table 5: Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date 11
Table 6: Immunohaematology Diagnostic Tests Companies - Pipeline Products by Stage of Development 12
Table 7: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development 13
Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
Table 9: ABO Diagnostic Test - Product Status 15
Table 10: ABO Diagnostic Test - Product Description 15
Table 11: Amity University Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: Blood Group Testing Kit - Product Status 16
Table 13: Blood Group Testing Kit - Product Description 16
Table 14: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 17
Table 15: Blood Screening Immunosignaturing - Product Status 17
Table 16: Blood Screening Immunosignaturing - Product Description 17
Table 17: Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 18
Table 18: Blood Typing System - Product Status 18
Table 19: Blood Typing System - Product Description 18
Table 20: Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
Table 21: NEO Iris - Product Status 19
Table 22: NEO Iris - Product Description 19
Table 23: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 20
Table 24: ORTHO AutoVue - Rare Sera Assay - Product Status 20
Table 25: ORTHO AutoVue - Rare Sera Assay - Product Description 20
Table 26: ORTHO BioVue - Rare Sera Assay - Product Status 21
Table 27: ORTHO BioVue - Rare Sera Assay - Product Description 21
Table 28: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 22
Table 29: ALBAclone Anti-C beta Reagent - Product Status 22
Table 30: ALBAclone Anti-C beta Reagent - Product Description 23
Table 31: ALBAclone Anti-e beta Reagent - Product Status 23
Table 32: ALBAclone Anti-e beta Reagent - Product Description 23
Table 33: ALBAclone Anti-H Reagent - Product Status 23
Table 34: ALBAclone Anti-H Reagent - Product Description 24
Table 35: ALBAcyte O Adult i Cell Reagent - Product Status 24
Table 36: ALBAcyte O Adult i Cell Reagent - Product Description 24
Table 37: ALBAcyte O RhD VI Reagent Cells - Product Status 24
Table 38: ALBAcyte O RhD VI Reagent Cells - Product Description 25
Table 39: Eluate Kit - Product Status 25
Table 40: Eluate Kit - Product Description 25
Table 41: MosaiQ IH Microarray - Product Status 25
Table 42: MosaiQ IH Microarray - Product Description 26
Table 43: Polyagglutionation Kit - Product Status 26
Table 44: Polyagglutionation Kit - Product Description 26
Table 45: Sensitivity Kit Anti-S, K, e, C - Product Status 26
Table 46: Sensitivity Kit Anti-S, K, e, C - Product Description 27
Table 47: TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
Table 48: HLAssure SE A Locus SBT Kit - Product Status 28
Table 49: HLAssure SE A Locus SBT Kit - Product Description 28
Table 50: HLAssure SE B Locus SBT Kit - Product Status 29
Table 51: HLAssure SE B Locus SBT Kit - Product Description 29
Table 52: HLAssure SE C Locus SBT Kit - Product Status 29
Table 53: HLAssure SE C Locus SBT Kit - Product Description 29
Table 54: HLAssure SE DQB Locus SBT Kit - Product Status 30
Table 55: HLAssure SE DQB Locus SBT Kit - Product Description 30
Table 56: HLAssure SE DRB-EX Locus SBT Kit - Product Status 30
Table 57: HLAssure SE DRB-EX Locus SBT Kit - Product Description 30
Table 58: TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 31
Table 59: LTA003 LISA-TRACKER Anti-Adalimumab - Product Status 32
Table 60: LTA003 LISA-TRACKER Anti-Adalimumab - Product Description 32
Table 61: LTC003 LISA-TRACKER Anti-Certolizumab - Product Status 33
Table 62: LTC003 LISA-TRACKER Anti-Certolizumab - Product Description 33
Table 63: LTE003 LISA-TRACKER Anti-Etanercept - Product Status 33
Table 64: LTE003 LISA-TRACKER Anti-Etanercept - Product Description 34
Table 65: LTG003 LISA-TRACKER Anti-Golimumab - Product Status 34
Table 66: LTG003 LISA-TRACKER Anti-Golimumab - Product Description 34
Table 67: LTI003 LISA-TRACKER Anti-Infliximab Assay - Product Status 35
Table 68: LTI003 LISA-TRACKER Anti-Infliximab Assay - Product Description 35
Table 69: LTR003 LISA-TRACKER Anti-Rituximab Assay - Product Status 35
Table 70: LTR003 LISA-TRACKER Anti-Rituximab Assay - Product Description 36
Table 71: LTT003 LISA TRACKER Anti-Tocilizumab Assay - Product Status 36
Table 72: LTT003 LISA TRACKER Anti-Tocilizumab Assay - Product Description 36
Table 73: LTTR003 LISA-TRACKER Anti-Trastuzumab Assay - Product Status 37
Table 74: LTTR003 LISA-TRACKER Anti-Trastuzumab Assay - Product Description 37
Table 75: LTU003 LISA-TRACKER Anti-Ustekinumab Assay - Product Status 37
Table 76: LTU003 LISA-TRACKER Anti-Ustekinumab Assay - Product Description 38
Table 77: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 39
Table 78: Aegis - Blood Grouping Assay - Product Status 39
Table 79: Aegis - Blood Grouping Assay - Product Description 39
Table 80: Aegis - Anti-A Quantitation In Group O Platelets - Product Status 40
Table 81: Aegis - Anti-A Quantitation In Group O Platelets - Product Description 40
Table 82: Aegis - Antibody Screening And Identification Assay - Product Status 40
Table 83: Aegis - Antibody Screening And Identification Assay - Product Description 41
Table 84: Aegis - Feto-maternal Hemorrhage Assay - Product Status 41
Table 85: Aegis - Feto-maternal Hemorrhage Assay - Product Description 41
Table 86: Aegis - Platelet Cross-match Assay - Product Status 42
Table 87: Aegis - Platelet Cross-match Assay - Product Description 42
Table 88: Aegis - Residual A Quantitation Assay - Product Status 42
Table 89: Aegis - Residual A Quantitation Assay - Product Description 43
Table 90: Aegis - rWBC Quantitation Assay - Product Status 43
Table 91: Aegis - rWBC Quantitation Assay - Product Description 43
Table 92: AEGIS System - Product Status 44
Table 93: AEGIS System - Product Description 44
Table 94: Glossary 104
1.2 List of Figures
Figure 1: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development 7
Figure 2: Immunohaematology Diagnostic Tests - Pipeline Products by Segment 8
Figure 3: Immunohaematology Diagnostic Tests - Pipeline Products by Territory 9
Figure 4: Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path 10
Figure 5: Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date 11

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report